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Abstract
Background: An effectiveness assessment on ASCT in locally advanced and metastatic breast cancer identified
serious ethical issues associated with this intervention. Our objective was to systematically review these aspects by
means of a literature analysis.
Methods: We chose the reflexive Socratic approach as the review method using Hofmann’s question list,
conducted a comprehensive literature search in biomedical, psychological and ethics bibliographic databases and
screened the resulting hits in a 2-step selection process. Relevant arguments were assembled from the included
articles, and were assessed and assigned to the question list. Hofmann’s questions were addressed by synthesizing
these arguments.
Results: Of the identified 879 documents 102 included arguments related to one or more questions from
Hofmann’s question list. The most important ethical issues were the implementation of ASCT in clinical practice on
the basis of phase-II trials in the 1990s and the publication of falsified data in the first randomized controlled trials
(Bezwoda fraud), which caused significant negative effects on recruiting patients for further clinical trials and the
doctor-patient relationship. Recent meta-analyses report a marginal effect in prolonging disease-free survival,
accompanied by severe harms, including death. ASCT in breast cancer remains a stigmatized technology. Reported
health-related-quality-of-life data are often at high risk of bias in favor of the survivors. Furthermore little attention
has been paid to those patients who were dying.
Conclusions: The questions were addressed in different degrees of completeness. All arguments were assignable
to the questions. The central ethical dimensions of ASCT could be discussed by reviewing the published literature.
Background
A systematic review on the effectiveness of autologous
stem cell transplantation (ASCT) in locally advanced
and metastatic breast cancer by the German Institute
for Quality and Efficiency in Health Care (IQWiG) [1]
indicated important ethical issues associated with the
use of this technology in clinical practice.
Among others, ASCT is a potentially curative treat-
ment option in locally advanced and metastatic breast
cancer, a life-threatening disease. Immediately after
high-dose chemotherapy, a woman is transfused with
their own stem cells, which were harvested before high-
dose chemotherapy begun. Apart from damaging tumor
cells, high-dose chemotherapy also damages vital hema-
topoietic stem cells, so ASCT replaces the destroyed
bone marrow. The potential benefit of extending patient
overall survival or disease-free survival is accompanied
by severe toxicities such as infections, bleeding, second-
ary malignancies, infertility etc. - including the risk of
therapy-induced death.
Objectives
In light of the existing benefit-harm balance, we decided
to systematically review the ethical issues related to the
use of this technology by analyzing the published litera-
ture. Because in ethics systematic reviews are not as
widespread as in medicine, our aim was to reveal the
* Correspondence: Sigrid.Droste@iqwig.de
1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne,
Germany
Full list of author information is available at the end of the article
Droste et al. BMC Medical Ethics 2011, 12:6
http://www.biomedcentral.com/1472-6939/12/6
© 2011 Droste et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
feasibility of conducting a systematic review in ethics.
This was done by analyzing the relevant literature.
Methods
We undertook a systematic review of the published lit-
erature on ethical issues related to ASCT in locally
advanced and metastatic breast cancer patients. Our
workflow consisted of the following working steps:
-Choosing the methodological approach to review
ethical issues related to health technologies,
-Searching for the existing publications by doing a
systematic literature search,
-Selecting the retrieved documents by applying pre-
defined inclusion and exclusion criteria,
-Abstracting the relevant data (arguments) and
assessing their validity,
-Synthesizing the qualitative data,
-Addressing Hofmann’s questions.
The review process was done by a multidisciplinary
team: one author conducted the information retrieval
(incl. pre-screening) while screening, reviewing and
summarizing the results were done by all authors - inter
alia an ethicist.
Methodological approach
Several methods do exist to consider ethical issues in
HTA [2]. We chose the reflexive Socratic approach for
our analysis by using Hofmann’s question list as a pilot
scheme [3]. This question list includes 33 questions on
ethical issues and values of health technologies, their
use and their assessment. In detail, these are:
-Moral issues (harm to patients, patient autonomy,
religious, social or cultural convictions),
-Questions with respect to stakeholders (such as
interests of producers or users),
-Questions related to technology (such as the moral
relevance of a possible existing symbolic value of a
technology),
-Moral aspects of methodological choices (such as
representativeness of clinical study populations for
users in clinical practice),
-Questions related to technology assessment (such as
moral consequences of the HTA).
Applying Hofmann’s question list to ASCT resulted
in a presentation of a wide variety of qualitative argu-
ments. To present the results in a more transparent
and reproducible way, we refrained from summariz-
ing the results according to the dimensions of the
question list, but rather addressed each question in
detail.
Information retrieval
We conducted a systematic, comprehensive literature
search in the cited biomedical, psychological and ethics
databases (January 2008, see Table 1). This process,
adapted to the specific needs of information retrieval on
ethical issues of health technologies, comprises systema-
tic retrieval in addition to narrative searching such as
snowballing and citation tracking [4]. The search com-
mand and strategy building facilities - particularly in the
ethics databases - are restricted. Thus the retrieval partly
included a pre-screening of the bibliographic data by
means of defined inclusion and exclusion criteria.
These pre-screening criteria were based on back-
ground knowledge of the technology. The searches were
very sensitive in order to avoid excluding any possibly
relevant publication. No language restrictions were
introduced. The information retrieval process has been
published previously in detail [5].
Pre-screening inclusion criteria (relevant to Ethics
databases)
-Publications on stem cell research or use,
Table 1 List of bibliographic databases which were included in the information retrieval process
Biomedicine International: Cochrane Database of Methodology Studies, Cochrane Central Register of Controlled Trials, Cochrane
Database of Systematic Reviews, BIOSIS, EMBASE, MEDLINE, NHS DARE, NHS HTA, SCISEARCH
National: CCMED
Nursing International: CINAHL
Psychology International: PSYCINFO
National: PSYNDEX
Social Sciences International: SOCIAL SCISEARCH
National: SOFIS
Health Economics International: NHS EED
Ethics International: EURETH, ETHX
National: BELIT
Monographs International: LocatorPlus
National: Karlsruher virtueller Katalog (KVK)
Publisher
databases
Elsevier (ScienceDirect), Thomson Reuters (Journals@OVID), Karger, Kluwer, Springer, Thieme
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-Publications of the German National Ethics Coun-
cil, key publications of the European Union on stem
cell research and therapy or substantial work on
pros and cons of stem cell research,
-Publications on adverse events/harms of stem cell
therapy,
-Publications on stem cell therapy regardless of kind
and origin of cells (embryonic, autologous, cord
blood etc.),
-Health economic publications on stem cell trans-
plantation, -Publications on survival or quality of life
post-stem cell transplantation,
-Substantial monographs suggesting matters relevant
to stem cell therapy.
Pre-screening exclusion criteria
-Journal articles in which the title solely refers to
embryonic stem cell research, importing of embryo-
nic stem cells, children, or indications other than
breast cancer,
-Publications recognizable as basic research (e.g.
dealing with chimerism),
-Publications on the position of religious groups
regarding stem cell research,
-Publications exclusively linked to regions outside of
Europe,
-Newspaper articles or other non-scientific journals.
Selecting the retrieved information
Two reviewers selected the identified documents based
on title and abstract (where available). In the case of dis-
sent, a third reviewer was consulted. If relevant, or in
the case of doubt, full-text articles were obtained.
Included were all documents that fulfilled one or more
inclusion criteria or did not fulfill one or more exclusion
criteria. Inclusion and exclusion criteria for selection
were as follows:
First and second screening inclusion criteria
-Publications on stem cell research,
-Publications by the German National Ethics Coun-
cil, key publications of the European Union on stem
cell research and therapy - or substantial work on
pros and cons on stem cell research,
-Publications on stem cell therapy (inclusive of
adverse events/harms),
-Health economic publications on stem cell trans-
plantation, balancing benefit and harm,
-Publications on quality-of-life in patients after
ASCT.
First and second screening exclusion criteria
-Publications which did not explicitly deal with ethi-
cal issues of ASCT in breast cancer
-Daily newspaper articles or other non-scientific
journals,
-Publications on embryonic stem cell therapy con-
taining no arguments on ethical issues related to
stem cell transplantation in breast cancer patients,
-Publications on stem cell therapy in children or
indications other than breast cancer with no rele-
vance to ethical issues in breast cancer patients,
-Publications on results of basic research
-Publications on descriptive pre-post health quality-
of-life studies without arguments related to ethical
issues
-Publications on the position of religious groups
regarding stem cell research containing no informa-
tion on the position of these groups regarding auto-
logous stem cell therapy,
-Publications exclusively linked to regions outside of
Europe, for example stem cell therapy in the
Philippines
The included full-text articles were then analyzed with
regard to qualitative arguments on ethical issues. The
relevant arguments were assembled and extracted by
using excerpts or paraphrasing and assessed for their
validity and relevance. The synthesized arguments were
then assigned to the dimensions of Hofmann’s question
list and the related question/s [3].
Finally, Hofmann’s 33 questions were addressed by
using these arguments. Only a small number of ques-
tions, such as on the interests of the reviewers (Q30),
could not be addressed by literature analysis. These
questions were answered by the reviewers themselves.
Results
Searching the 27 databases we identified 879 titles, 356
of which were screened by using title and abstract. Of
these 120 were screened in full text and considered rele-
vant to our research question. Finally, after adjusting for
remaining duplicates (e.g. duplicate publications in dif-
ferent languages) and for those documents later found
to meet the exclusion criteria, the remaining 102 publi-
cations comprised one or more arguments with regard
to one or more questions in the checklist (Figure 1). We
used Hofmann’s question list to analyze these
documents.
Publication language was mainly English (88 publica-
tions = 86%), followed by German (11 publications =
11%), French (2 publications = 2%) and Swedish (1 pub-
lication = 1%). Some publications comprised only a few
sentences on ethical issues. The main objectives of the
articles, and fields of the authors, were wide-ranging
(see Table 2).
Study design also varied among the 102 included pub-
lications (see Table 3). Levels of evidence were not
assigned to the literature.
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Overall, 30 of the 33 questions were addressed by the
identified publications: Question 8 (Q8) and question 32
(Q32) were not addressed, while question 30 (Q30) had
to be answered by the authors of this review. For
detailed information see figure 1.
Hofmann’s Question list
We found some relevant arguments in the published lit-
erature for all Hofmann’s dimensions, each of which
was concerned with the use of ASCT in breast cancer
patients. These dimensions included “moral issues”
(questions1-16), “questions with respect to stakeholders”
(questions 17-20), “questions related to technology”
(questions 21-23), “moral aspects of methodological
choices” (questions 24-28) and “questions related to
technology assessment” (questions 29-33). In addition to
patients, physicians, nurses and relatives, societal values
were affected by the use of this technology. According
to the different weight of the dimensions and questions,
the frequency of addressing them by publications varied
widely (Table 4).
We synthesized the relevant arguments from the pub-
lished literature addressing each question of Hofmann’s
question list separately. The answers to Q12, Q29 to
Q33 are partly or completely written by the authors of
this review. All other parts are summaries and para-
phrases of the published literature.
Figure 1 Flowchart on the selection process of the information
retrieval result.
Table 2 Main objectives of the included 102 articles and
specialism of the authors
Main objective/specialism Number of
publications1
Ethical issues 35 (34%)
Ethics + Law/Quality of life/Psychology/Health
Economics/Health Policy
4 (4%)
Legal issues 15 (15%)
Law + Health Policy 2 (2%)
Medical issues/effectiveness evaluation 12 (12%)
Quality of life research 10 (10%)
Quality of life + psychology 3 (3%)
Psychological issues 9 (9%)
Health Economics 4 (4%)
Health Policy 4 (4%)
Socio-cultural issues 1 (1%)
Others 3 (3%)
1 Some publications referred to more than one single main objective.
Table 3 Publication design of the included 102 articles
Publication Design Number of publications
Review literature
HTA report 4 (4%)
Systematic review 6 (6%)
Review article 26 (25%)
Expert statement/Newspaper article 20 (20%)
Opinion (parliamentary/scientific society etc.) 5 (5%)
Dissertation 2 (2%)
Editorial 5 (5%)
Commentary/letter 8 (8%)
Primary literature
Randomized controlled trial 2 (2%)
Prospective observational/cohort study 4 (4%)
Retrospective observational/cohort study 7 (7%)
Prospective longitudinal study 4 (4%)
Cross-sectional study 2 (2%)
Qualitative research study 5 (5%)
Case report 2 (2%)
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Questions “Moral issues” (Q1 to Q16)
Q1 What are the morally relevant consequences of the
implementation of the technology? Several ethical
issues have been addressed in numerous articles with
regard to autologous stem cell transplantation in breast
cancer patients [6-24]. In the late 1980s, ASCT appeared
to be a highly promising treatment for high risk and
metastatic breast cancer patients and was introduced
Table 4 Number of publications with arguments related to the dimensions and questions of Hofmann’s question list
Dimension/Question Number of publications with related
arguments (N = 102)
Moral issues 81
Q1 What are the morally relevant consequences of the implementation of the technology? 18
Q2 Does the implementation or use of the technology challenge patient autonomy? 24
Q3 Does the technology violate or interfere with basic human rights in any way? 2
Q4 Does the technology challenge human integrity? 9
Q5 Does the technology challenge human dignity? 4
Q6 Will there be a moral obligation related to the implementation and use of a technology? 11
Q7 Does the technology challenge social values and arrangements? 3
Q8 Does the widespread use of the technology change our conception of certain persons? 0
Q9 Does the technology contest religious, social or cultural convictions? 1
Q10 Can the use of the technology in any way challenge relevant law? 2
Q11 How does the assessed technology relate to more general critiques of modern medicine? 16
Q12 Are there any related technologies that have turned out to be morally challenging? 2
Q13 Does the technology in any way challenge or change the relationship between physician
and patient?
5
Q14 How does the implementation of the technology affect the distribution of health care? 23
Q15 How does the technology contribute to or challenge professional autonomy? 2
Q16 Can the technology harm the patient? 23
Questions with respect to stakeholders 19
Q17 What patient group is the beneficiary of the technology? 10
Q18 Are there third party agents involved? 5
Q19 What are the interests of the users of the technology? 7
Q20 What are the interests of the producers of technology (industry, universities)? 1
Questions Related to Technology 11
Q21 Are there moral challenges related to components of a technology that are relevant to the
technology as such?
1
Q22 What is the characteristic of the technology to be assessed? 2
Q23 Is the symbolic value of the technology of any moral relevance? 9
Moral Aspects of Methodological Choices 35
Q24 Are there morally relevant issues related to the choice of end points in the assessment? 19
Q25 Are there morally relevant issues related to the selection of meta-analysis and studies to be
included in the HTA?
9
Q26 Are the users of the technology in the studies representative of the users that will apply it
in clinical practice?
5
Q27 Are there morally relevant aspects with respect to the level of generalisation? 2
Q28 Are there moral issues in research ethics that are important to HTAs? 18
Questions Related to Technology Assessment 9
Q29 What are the reasons that this technology is selected to be assessed? 2
Q30 What are the interests of the persons participating in the technology assessment? 0
Q31 At what time in the development of the technology is it assessed? 1
Q32 Are there related technologies that have or have not been assessed? 4
Q33 What are the moral consequences of the HTA? 2
(N = 102)
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into clinical practice without further evaluation in clini-
cal trials. Belanger et al. [25] described in a 1991 survey
that 80% of oncologists claimed that they would offer
ASCT to their patients.
However, since the new procedure also caused toxic
side effects, patients were faced with the decision to
consent to a hopefully life-prolonging but also poten-
tially fatal treatment. This decision had to be taken in
the context of extensive promotional media campaigns
and without reliable data or independent patient infor-
mation. In addition, in the late 1990s, the first rando-
mized trials were started. However, due to early
introduction of ASCT into clinical practice only a small
number of patients received the treatment within clini-
cal trials. The majority of the first investigational trials
did not showing any benefit of ASCT in terms of overall
survival. Moreover, the only two trials which showed
benefit in survival were found to be fraudulent (Bez-
woda fraud). Premature introduction into clinical prac-
tice, overly optimistic presentation of preliminary results
in the media and the subsequent fraudulent trial had
significant effects on further research and the doctor-
patient relationship. Recruiting patients for further clini-
cal trials became even more difficult due to lack of trust
in oncology and the trial investigators. Sledge et al [22]
pointed to the possibility of potential benefit of ASCT
in spite of the falsified data. Recent meta-analyses con-
firmed this assumption by showing a marginal effect in
prolonging disease-free survival [1,26-28]. Nevertheless,
ASCT in breast cancer remains a stigmatized
technology.
Q2 Does the implementation or use of the technology
challenge patient autonomy? ASCT may change
patient autonomy in both directions [7,8,13,23,29-49].
While referred to as the ultimate therapeutic option if
all other alternatives have failed (extended autonomy), it
is associated with severe side effects and a high risk of
mortality (reduced autonomy). Many of the identified
papers stressed the need for detailed information on
benefit and risks of ASCT before consent is obtained
[40,46]. Some authors criticize that patients are insuffi-
ciently informed and patient understanding is not
ensured [30]. Patient autonomy can only be improved if
decision-making results from substantial, reliable and
comprehensible patient information. Moreover, many of
the patients experienced substantial economic con-
straints, since many parts of the therapy are not reim-
bursed by their health plan [43]. Further issues of
patient autonomy and informed consent are discussed
in Q3, Q4, Q11, Q16 and Q23.
Q3 Does the technology violate or interfere with basic
human rights in any way? Some issues relating to
human rights were found in the literature on the
application of ASCT itself and its history and implemen-
tation process. Examples of the latter:
-violation of informed consent before treatment,
-specific vulnerability of the population undergoing
treatment towards serious toxicities,
-using ASCT when more effective and safer proce-
dures exist, and
-(of minor concern in ASCT) funding of treatment
with or research on human stem cells
are all in violation of basic human rights such as
autonomy and treating palliative patients with dignity
[50]. Furthermore, beneficial therapy in a life-threaten-
ing situation might be impeded, since, to date, it is
unknown whether there is any evidence of a benefit of
ASCT for some subgroups of breast cancer patients
[23].
Q4 Does the technology challenge human integrity?
By using human cells for ex vivo manipulation and ther-
apeutic purposes, stem cell transplantation has changed
the image of humans and interfered with public values
[6,51,52]. The commercialization of stem cell transplants
or patenting of isolating adult stem cells (stem cells
modified between the time of harvesting and use - thus
warranting a change of property rights and, enabling
them to be used by third parties) also challenges human
integrity [32,53]. Moreover, in palliative situations some
patients undergo ASCT to avoid anything that could be
interpreted as a rebellion against their caregivers. Being
highly dependent on them, these patients may consent
to high-risk therapies that might do more harm than
good [54]. Whether ASCT challenges the individual’s
human integrity depends on the individual’s values and
the extent of informed consent. Presenting phase II
results and then falsified data prevented the patients
from preserving their integrity [39,47,49].
Q5 Does the technology challenge human dignity?
This question also depends on the fundamental cultural
interpretations of the concept of human dignity and its
representation in constitutional law [55]. This includes a
reflection on whether commercialization and patenting of
human stem cells or their isolation procedure or research
on human stem cells (a minor problem in autologous
transplantation) is compatible with a universal or specific
concept of human dignity [32,53,56]. Results of stem cell
research and their presentation by media encouraged the
public’s belief that curative treatments for chronic diseases
in general would soon be available [55]. Moreover, the
autologous variant of stem cell transplantation carries
some risk of challenging human dignity, e.g. it has raised
hope for an existing treatment option and ultimately a
cure, thus preventing a dignified death [56].
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Q6 Will there be a moral obligation related to the
implementation and use of a technology? There has
been an important moral obligation attached to ASCT
regarding the debate on the “imperative of technology”
in terms of imperative of possibilities [57]: the new high
technology (thought to be a true innovation) with the
potential to benefit women with a life-threatening dis-
ease raised new hope for patients and physicians
[18,58,59]. The basic problem was caused by the prema-
ture implementation before evaluation and clinical prac-
tice use in the 1990s. Implementation was based on
phase II evidence [18,34]. In ASCT, it was not evidence
but enthusiasm, hope, emotions and finally court deci-
sions that opted for implementation before evaluation
[11,24,50,60]. This implementation on limited evidence
impeded the identification of those patient groups that
would benefit (most) and the research on alternatives
[61,62].
Q7 Does the technology challenge social values and
arrangements? There are few references to the chal-
lenge of social values by ASCT. When a “last chance
therapy” emerges, the hitherto fatal disease seems to
become manageable and near-possible death becomes
less proximate or is still considered avoidable by
patients and the public. As a consequence, patients
postpone preparing for death [34,42].
Another point of interest is the financing of experi-
mental therapies such as ASCT based on health insur-
ance funds and their specific criteria. Diseases receive a
different level of significance if treatment options are
not covered by insurers in general, but could be covered
by them were fulfilling certain conditions to be meet,
such as like qualified documentation, enrolment in con-
trolled therapeutic studies, etc. as in the case of ASCT
[63]. See also Q18.
Q8 Does the widespread use of the technology change
our conception of certain persons? No indication could
be found in the literature on changes in the conception
of women with breast cancer with regard to ASCT.
However, there may be some changes, which were not
discussed by literature.
Q9 Does the technology contest religious, social or
cultural convictions? No indication could be identified
on convictions of any religious, social or cultural group
with regard to ASCT. Moreover, Jehovah’s Witnesses
did not offer any objection to this autologous variant of
stem cell transplantation [64]. There may be some reli-
gious, social or cultural groups outside of the German/
European focus with relevant convictions regarding
ASCT which were undiscovered by the information
retrieval and the defined inclusion and exclusion criteria.
Q10 Can the use of the technology in any way chal-
lenge relevant law? Autologous stem cell transplanta-
tion did not change the relevant law - contrary to
embryonic stem cell research. But the judiciary played a
decisive role in ASCT history - particularly in the USA.
The legal and political pressure led most health insur-
ance funds to pay for ASCT by the mid-1990s [18]. As
most of the later trials did not show distinct superiority
of ASCT compared to conventional chemotherapy in
breast cancer, coverage policy by insurers become more
restrictive, i.e. denying coverage [24].
Q11 How does the assessed technology relate to more
general critiques of modern medicine? One of the
main problems of ASCT discussed in the literature is
the conflict of values between rapid access to an experi-
mental therapy for those patients for whom conven-
tional therapies offer little hope, and attempts to protect
patients from therapies that are unproven (or expensive
or potentially harmful) or even inferior to existing thera-
pies [58,65]. This is a general conflict between technical
and medical progress, carrying the danger of implement-
ing an experimental therapy as standard therapy
[19,65-67]. It includes an inherent conflict between the
obligation of a physician to treat optimally and the pub-
lics need to have a procedure’s effectiveness evaluated
and protect the integrity of the evaluation process
[41,58,68].
Furthermore, according to Davies [69], the media and
general public did not seem to wish to recognize the
limitations of medicine and the inability of physicians to
cure every disease. Therapeutic concepts based on
human stem cells contribute to an image of “repairing
medicine” to injuries with disease character [70].
Furthermore, modern medicine pursues the “tendency
to focus on the status of the body rather than the
patient as a holistic person”.
Hence, research funding is more focused on improv-
ing disease outcome than it is on the demands of
patients who are dying [71] and on the tolerance and
preferences of those individuals [51], thus drawing
attention away from more appropriate efforts to mini-
mize symptoms and enhance the quality of life for term-
inally ill patients and their families [35].
If experimental treatment is available outside of trials
it is difficult to recruit patients for clinical trials. In
ASCT trials the recruiting phases had to be greatly
extended. As a result, it became necessary to legitimize
evaluation, while the evaluation process progressed
more slowly than the diffusion of clinical use. In addi-
tion no subgroup analysis has been done [19,23,35,68].
Lambird [41] argues that false hopes are raised in
patients offering to participate in research protocols
because the enthusiasm of the investigators often
obstructs precise clinical research. In ASCT, conclusions
have been drawn before evaluating phase III data [37].
In contrast, Rushing [72] poses the question: is it ethical
to recruit patients for phase III trials to confirm the
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benefits of survival that had previously been demon-
strated in phase II trials?
Finally, important lessons from ASCT related to mod-
ern medicine are the collateral effects of both imple-
menting a technology without evaluating its
effectiveness and the Bezwoda fraud. The physician-
patient relationship (physicians’ misguided and/or
enthusiastic recommendations), patients’ informed con-
sent on the basis of manipulated data, and the resulting
patient harm are of concern. This Bezwoda fraud not
only contradicts the ethical principle of “first do no
harm” (primum non nocere), it also has consequences
for all oncologists and the discipline itself. It is not yet
clarified whether ASCT in breast cancer might save or
extend lives. Oncology has become untrustworthy and
all oncologists are confronted with the falsified data.
Patients become less recruitable for clinical trials. Both
the University of Johannesburg and South African scien-
tists in general are affected by the association with Bez-
woda. Science itself is also affected because science is
based on confidence and if a scientist presents his/her
data publicly, the data are accepted as fact. Unethical
and dishonest clinical experiments tend to have devas-
tating, long-term consequences on honest, ethical
experiments [22].
Evans [58] is critical of an institutional deficit in the
relationship between clinical researchers, attending phy-
sicians, insurers and institutions like the National Can-
cer Institute, and of the supervision of the evaluation of
medical procedures as they move from small hypotheses
to large RCTs.
Q12 Are there any related technologies that have
turned out to be morally challenging? Today, the
most morally challenging related technology is the so-
called cord blood transplantation [32]. For this type of
transplantation, many issues concerning children’s and
parents’ rights and the large field of commercialization
are currently being discussed. Controversy also abounds
around allogeneic stem cell transplantation [73], which
exerts an even higher toxic profile than ASCT [61].
Q13 Does the technology in any way challenge or
change the relationship between physician and
patient? Two main issues are discussed in the relevant
literature [15,22,31,72,74]. After the Bezwoda fraud was
published, it became almost impossible to recruit
patients for further phase III trials [72] because of
patients’ loss of trust in their physicians and their
recommendations. Moreover, the demand for indepen-
dent, true and honest information has increased. Doc-
tors might be too optimistic about the benefits of ASCT
and afraid to explain the true risks of this treatment.
Patients might be unrealistically optimistic [15]. Life-
threatening situations and high-risk therapies are often
associated with an emotional crisis in patients. This
could interfere with clear communication of benefits
and risks [74]. Cohen adds that isolation creates a spe-
cial dependency of the patient on nurses and physicians
[31].
Q14 How does the implementation of the technology
affect the distribution of health care? Actually, there
are no distributional issues of health care. The frequency
of use of ASCT in breast cancer patients now is low, but
it is still an expensive treatment compared to alterna-
tives. In the 1990s, there were strong concerns relating
to coverage of treatment costs, allocation of resources,
equity and justice - especially in the United States.
Authors described considerable regional and local differ-
ences in the coverage of ASCT. Some insurers offered
no coverage while others covered the treatment only
within studies, or both within and outside of studies.
Equality was not guaranteed between breast cancer
patients. Due to pressure from politics, media, the pub-
lic and from court decisions from the mid-1990s, almost
all insurers covered ASCT - though they designated it
as investigational or experimental. Thus, equality
between breast cancer patients has been guaranteed, but
prioritizing ASCT tied up enormous resources of the
insurers and left less financial resources for other dis-
eases/patients [10,12,15,21,34,36,37,61,65,75-79].
Publications since the Bezwoda fraud was published
discuss the problem of treatment coverage without evi-
dence of effectiveness and the need to ensure coverage
of investigational or experimental therapies in studies
only [6,14,24,80-82]. The general public, rather than
insurers, should decide resource allocation, not insurers
[83]. Research on human stem cells calls for basic social
requirements, resources for supervision and the preven-
tion of any abuse [70]. The problem of last chance
therapies still remains that are ineffective, but not to
cover this “may create the impression that critically-ill
patients are being abandoned in their moment of need
[84]“.
Q15 How does the technology contribute to or chal-
lenge professional autonomy? Two papers referred to
this item [15,22]. Kletzel describes the potential role
conflict of being a physician treating the individual
patient and being an investigator interested in enrolling
a patient in his/her clinical trial [15]. Sledge argues that
ASCT could be an effective intervention but following
the Bezwoda fraud testing this hypothesis in a new clini-
cal trial could hardly be realized [22]. Not only patients
but also physicians trust in research, and scientific pub-
lication has been affected by Bezwoda (cf. Q11). This
leads to reduced professional autonomy.
Q16 Can the technology harm the patient? All publi-
cations agree that ASCT contains a considerable harm
potential. Insurers, as well as researchers, are reporting
that ASCT is highly toxic - including treatment-related
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mortality and potentially fatal infections and long-term
toxicities [21,70,71,77,85-87]. Besides these severe or
serious adverse events, some negative impact on qual-
ity of life in the survivors is reported, such as psycho-
social problems or depression symptoms [43,71,74,88].
Long-term studies suggest that younger women are
more exposed to harm concerning emotional status,
anxiety, depression, sleeping disorders, sexual activity,
aims of life, isolation of their children, length of reha-
bilitation, etc. [31,89,90]. Clinical changes in ASCT by
using additional growth factors and other supportive
therapies may cause fewer long-term side effects
[91,92].
Benefit and harm have not been considered in a
balanced way. Despite the obvious risks of ASCT, possi-
ble benefits have been given closer attention than harms
and little attention has been paid to those patients who
were dying from ASCT [61,71].
Besides adverse events, there are the ethical principles
of beneficence and to do no harm which are relevant
for describing harm. These principles do not seem to
have been fulfilled - particularly in the 1990s - due to
the absence of sufficient patient information, true and
honest information (cf. Q2) and informed decision-mak-
ing abilities unaffected by stakeholder interests
[19,70,78,93]. “The physician and patient should both
undertake self-examination to ensure the treatment is
being carried out for the right reasons [79]“.
The problem of weighing patient-centered against
population-centered harms by insurers is also discussed.
Avoiding population-centered harms from imprudent
use of shared resources leads to “coverage only for last-
chance treatments that meet a threshold of established
net benefit and payment for unproven therapies only in
the context of controlled clinical trials, in which a
patient might receive a placebo or the standard treat-
ment [84]“.
Questions “Questions with respect to stakeholders” (Q17 to
Q20)
Q17 What patient group is the beneficiary of the
technology? Recent meta-analyses [1] report a marginal
effect in prolonging disease-free survival, accompanied
by severe harms including death. It is unknown to date
if there is a greater benefit from ASCT to any subgroup
of patients and, if so, whether this group would benefit
more from an existing alternative. Perhaps only those
women in palliative care who value any treatment higher
than doing nothing would benefit from ASCT.
Reports published since 2001 discuss the right of
patients to aggressive, toxic and expensive treatment -
even those that have been untested and have demon-
strated insufficient evidence on effectiveness and safety -
if they are potentially life-saving or life-prolonging
[19,60,94].
In the 1990s, when ASCT was regarded as beneficial
to all or most breast cancer patients, issues of fairness
and justice were discussed in the literature: independent
access, distribution and inequality due to different cov-
erage policies. These issues refer to prioritizing of ASCT
among breast cancer patients and breast cancer patients
versus patients with other diseases [15,45,67,95].
Authors expressed the hope of prompt clarification
around the question of which patient group would bene-
fit most and how the costs of ASCT could be estimated
[86].
Q18 Are there third party agents involved? There are
some third party interests: “the requirements of clinical
science, patient demands, physician advice to patients,
physicians’ beliefs and enthusiasm, patient advocacy, liti-
gation, economics (the cost of the procedure, insurers’
resistance to pay for investigational treatment), and
entrepreneurial oncology, politics, the ambivalent com-
mitment of oncology to randomized clinical trials, and
how the media reported the story [19]“.
Industry is interested in positive evaluation of ASCT
because it controls the whole process from cell sampling
via cell concentration to returning the cells to the
patient. This challenges the autonomy of the non-com-
mercial system of assembling blood products [52].
Initially, insurers claimed that ASCT was experimental
or investigative and did not cover this technology out-
side of clinical trials. But in the late 1990s, insurers
began covering ASCT because of court decisions, politi-
cal, media and public pressure (judicial bias favors indi-
vidual patients, not patient populations). For the
insurers, coverage without evidence was judged to be
cheaper than the risk of negative court decisions.
The individual patient is interested in using ASCT
because women feel they benefit from it, while the soci-
etal interest is not to damage the health insurance sys-
tem by requests for new cost-intensive and potentially
ineffective technologies [37,45,58].
Q19 What are the interests of the users of the technol-
ogy? Users are primarily physicians, who fulfill the dual
role of patient caretaker and researcher or study investi-
gator (cf. Q15). This resulted, particularly in the 1990s,
in conflicts of interest between benefits for the patient,
personal benefit for the physician and financial demands
[18,45,96]. “...there are financial incentives for holding
onto patients and for doing transplants ... Autologous
peripheral stem-cell transplant units are reportedly
money-makers for medical centers [79]“.
A progressive alliance of research and economy, public
interest and time pressure increases the risk of imple-
menting clinical trials before evidence is available. The
researchers present possible results of their projects and
create excessive expectations and hope among patients
with their promises of rapid therapeutic success [60,70].
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One paper addressed the ethical problem of not test-
ing autologous blood components with the goal of redu-
cing the risk of infections to staff and other patients
[97].
Q20 What are the interests of the producers of tech-
nology (industry, universities)? Actually, frequency of
ASCT application is low. Thus, there are fewer incen-
tives for producers and health professionals now than
there were in the 1990s. There is still some interest
from device manufacturers, health providers and univer-
sities and blood banks (which store the harvested blood
during high-dose chemotherapy) [73]. “The non-profit
agency will only charge what the stem cell unit costs,
but agencies can engage in a large variety of activities
which increase these costs” [98].
Questions “Questions Related to Technology” (Q21 to Q23)
Q21 Are there moral challenges related to compo-
nents of a technology that are relevant to the technol-
ogy as such? To address this question on conclusions
by analogy some background knowledge and input from
other technologies is needed. However, unfortunately
ASCT in other conditions and could not be extracted
entirely from the identified publications. Hence, in the
following we address some ethical issues identified to be
of importance in the treatment of oncology patients.
Ethical issues of quality-of-life measurement, the value
of life or of long-term quality-of-life studies in palliative
care correspond to ethical issues of ASCT in breast can-
cer patients (e.g. health-related quality-of-life data are at
high risk of bias in favor of the survivors). All ‘last
chance’ therapies are related to certain identical ethical
issues. New technologies for patients who are facing
death always create new hope. In addition, all treat-
ments - more or less aggressive -which induce death,
pain or other severe adverse events entail some similar
ethical issues. Moreover, values of patients who are
facing death are usually different from those of physi-
cians, nurses or relatives: They want to die with dignity.
Preparing patients for death is important in ASCT but
also in many other life-threatening diseases. Some of
these points are explained by Kelly [71].
Q22 What is the characteristic of the technology to be
assessed? The most important purpose of ASCT is
prolonging the survival or at least disease-free survival
of breast cancer patients after all other available treat-
ments have failed. This relates to such human and soci-
etal values as living as long as possible, free from
debilitating symptoms, and in dignity. These values are
partly discussed in the quality-of-life literature, but
rarely in the publications on ethical issues of ASCT.
Uncertainty is the most important factor at all stages
of transplantation. The purpose of preparing for ASCT
treatment should be to identify all patients whose
quality of life is so restricted that further treatment with
ASCT could not be seen as ethically problematic.
A major conflict of ASCT is the question of how
much information should be given before treatment.
“Nursing and medical staff routinely failed to inform
dying patients of their deteriorating condition.” ... “Such
denial of emotion, when not appropriately reflected
upon as a necessary strategy for dealing with very
uncomfortable events, avoids a context in which under-
standing and ways of coping may be developed [71]“.
Furthermore, patient characteristics are related to tech-
nology. The “patient’s progress is composed of constant
crises ... The patient is not either hopelessly terminal or
probably curable, but rather in a ‘high stakes’ limbo and
vacillations in hope, fears and anger emerge throughout
the process [44]“.
Q23 Is the symbolic value of the technology of any
moral relevance? ASCT is of great symbolic value. It
represents the dissemination of phase II trial results,
coverage without evidence, falsified data, high costs to
the public and considerable, unnecessary harm to
patients. Ethical issues are manifold
[18,22-24,65,76,85,94,98] and many are already discussed
in the aforementioned questions, e.g. Q1, Q2, Q13, Q14,
Q16.
Questions “Moral Aspects of Methodological Choices” (Q24
to Q28)
Q24 Are there morally relevant issues related to the
choice of end points in the assessment? Endpoints in
clinical trials or quality-of-life studies are highly affected
by values. Depending on age, gender, socio-cultural con-
text, family, religion, etc., valuing of survival, treatment-
related adverse events and quality-of-life outcomes look
very different. Long-term toxicities are more important
to younger patients. Prolonged survival time or shorter
treatment duration for equal survival or longer progres-
sion-free survival differ greatly in importance from one
patient to another or from the viewpoint of physicians
or researchers and patients. Survival probability is not
only linked to statistical data, but also to ethical and
psychological issues [10,44,99-101].
Hence, choosing and prioritizing endpoints also means
choosing and prioritizing values. Survival-related dates
are less important in palliative care than are quality-of-
life issues, while quality of life is considered less impor-
tant if there is a (marginal) chance of cure. In conclu-
sion, individualizing and contextualizing evidence of
endpoints is necessary [14,42,45,50,51,61,86,99,102-104].
But clinical trials and quality-of-life studies neglect the
complexity of relationships by mostly considering one-
dimensional measurement [38].
Choice of endpoints may also cause confounding of
results. In ASCT, lack of experience is considered to be
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responsible for treatment-induced mortality and nega-
tive impact on long-term outcome [42,94,105].
Few publications address the choice of endpoints and
their impact on economic evaluations even in the field
of ASCT. However, long-term toxicities are highly rele-
vant to cost-utility analyses [61,106].
Q25 Are there morally relevant issues related to the
selection of meta-analysis and studies to be included
in the HTA? Seven papers highlight this topic
[10,22,24,51,61,85,99]. Although the HTA report of
Johnson et al. included the falsified Bezwoda results, the
authors concluded that no definite recommendation
could be drawn from the existing data [61]. Bergh criti-
cizes the premature implementation of this technology
based only on available data from phase I/II trials [51].
It is also stated that unethical clinical experiments and
scientific misconduct cause long-lasting effects on trust
in science [22,85]. Other authors argue that it is often
very difficult to initiate a controlled trial if the interven-
tion is believed to have a very high likelihood of being
more effective than the control intervention [99].
Q26 Are the users of the technology in the studies
representative of the users that will apply it in clini-
cal practice? The use of ASCT has changed widely
since to the 1990s. According to the contemporary
availability of treatment alternatives, the users of ASCT
in the studies are not representative of the users in
today’s clinical practice.
Clinical practice could not reproduce the Bezwoda
trial results because of falsified data. The results are far
too exaggerated [22,85], and treatment-related mortality
“was related to lack of experience with high-dose treat-
ment”. That is, low-volume centers observed lower sur-
vival than high-volume centers [100], making the trials
only representative of highly specialized centers. Lee
argued that the history of ASCT “might be relevant to
other transplant programs and even other situations in
medicine where patients accept substantial risks in the
hope of a cure” [42].
Women who died from ASCT were not reasonably
represented if only those patients that survived treat-
ment were included in the trials (e.g. some quality-of-
life studies) [43].
Q27 Are there morally relevant aspects with respect
to the level of generalization? To date, ASCT in breast
cancer has been tested for both patient groups of rele-
vance, i.e. high-risk breast cancer patients with multiple
node positive disease and patients with distant metas-
tases. However, particularly in the early phase II trials, it
was likely that only selected patients were included in
these studies [78]. Recruitment was frequently stopped
in RCTs on metastatic breast cancer patients because of
low willingness in patients to participate. Consequently,
trials may be of poor statistical power [23].
Q28 Are there moral issues in research ethics that are
important to HTAs? Out of 18 papers discussing this
issue [18,21,22,24,34,60,61,78,79,85,86,94,98,99,107-110]
Smigel [78] gives the best summary of arguments:
“More than 90% of women (1989-1993 treated with
ASCT) did so outside of clinical trials (...). We are wast-
ing valuable information by not getting those patients
into clinical trials”. The fact that the Bezwoda trials had
not been approved by the local ethics and review com-
mittee together with the falsified publications led to
mistrust, dramatically reducing enrolment of patients in
prospective trials [108]. But the Bezwoda history did not
change attitudes to planning, enforcement and reviewing
of clinical studies - neither in the US nor in Europe
[107]. No statement from an ethical point of view could
be identified on the appropriateness of inclusion and
exclusion criteria, control groups or control
interventions.
Questions “Questions Related to Technology Assessment”
(Q29 to Q33)
Q29 What are the reasons that this technology is
selected to be assessed? The dissatisfactory outcome of
conventional chemotherapy in high-risk breast cancer is
one reason for assessing ASCT [61]. Even today, meta-
static breast cancer is considered to be an incurable dis-
ease. Since young women often die from this aggressive
disease, physicians are pressurized to offer aggressive
treatments [24]. Ten years after Bezwoda, effectiveness
assessment still flags up some major ethical issues, but
these have not been systematically assembled and
synthesized. These issues, which are similar in other
oncologic treatments, might be supplemented by some
non-obvious ethical issues. Additionally, ASCT in breast
cancer is, in fact, not media-covered. This was a pri-
mary criterion for the authors’ work on methodological
issues.
Q30 What are the interests of the persons participat-
ing in the technology assessment? The persons
involved in this review have been motivated by a desire
to find (in the context of no financial or other conflict
of interest) a conclusion for the affected women, in
which the benefits and harms are balanced. Another
objective is to find an eligible recommendation for
financing or not financing treatment by health insurers.
In addition, the involved persons are interested in find-
ing and applying a feasible method of integrating ethical
issues in effectiveness assessments.
Q31 At what time in the development of the technol-
ogy is it assessed? The assessment was done when the
Bezwoda fraud was well-known, in clinical practice
today only a few women are treated with ASCT and
alternative treatments are available and used in clinical
practice. This means the life cycle of the technology is
already advanced.
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Moreover, results of trials with more than 5-years’ fol-
low-up have been published, allowing the assessment of
long-term overall and disease-free survival in breast can-
cer patients treated with ASCT. Nevertheless, the bene-
fit of ASCT in special subgroups remains to be
elucidated [1,111].
Q32 Are there related technologies that have or have
not been assessed? A major challenge is the assessment
of cord blood transplantation [112-115]. While this
technology is related to ASCT, cord blood cells are
rarely used in clinical oncology. A few assessments on
cord blood transplantations have been done already, but
a comprehensive assessment of effectiveness and ethical
issues with current evidence should be conducted. Addi-
tionally, the importance of all types of allogeneic stem
cell transplantation [73] in breast cancer treatment has
not been clarified to date. An assessment of such trans-
plantations (in particular on the additional ethical issues
and differences compared to autologous transplantation)
could be helpful.
Modern imaging techniques in therapy monitoring (e.
g. positron emission tomography (PET), PET/CT) are
not yet standardized and still experimental in breast
cancer treatment. In cases of misdiagnosis these tech-
nologies may cause wrong landmark changes in thera-
peutic management. Furthermore, they have not yet
been assessed systematically from the ethical point of
view - and these technologies are not related to ASCT.
Q33 What are the moral consequences of the HTA?
“Safety should be the first order of the day” should be
the consequence of the assessment and impact on the
quality of health care [116]. There are proposals for cov-
erage of investigational treatments in terminal illness
within clinical trials (rigorous protocol review process
and thorough study overview comparing investigational
treatment with standard therapy) if “life expectancy is
limited, the investigational therapy provides the only
possibility to preserve life, the treatment is prescribed by
legitimate providers and performed in leading institu-
tions and conventional therapy has failed [116]“.
Depending on individual cases, decisions on coverage
are recommended.
Subsequent to the review of ethical issues, it is recom-
mended that subgroup analysis is conducted from exist-
ing data. Analysis of individual patient data has recently
begun [117,118]. It might be possible that, in the field of
ASCT, although phase III trials and meta-analyses were
undertaken, “expanded access ... would bring the doctors
back into the drug development process and, rather
than damage the clinical trial system, would greatly
expand its effectiveness and value [35]“.
Given that the ethical issues in the 1990s vary from
those of today, a short summary of the currently rele-
vant ethical issues of ASCT in breast cancer patients is
presented in Table 5.
Discussion
There are many ethical challenges related to the use of
autologous stem cell transplantation in advanced breast
cancer, both technological- and patient-related. Applying
the normative framework formed by Hofmann’s ques-
tion list as axiological information [3,57,119] resulted in
a comprehensive synthesis of qualitative arguments pub-
lished in the literature. As the IQWiG is explicitly dis-
tinct from decision-making bodies thereby fulfilling the
condition of the EUnetHTA HTA Core Model for medi-
cal and surgical interventions [2, page 84] which stated
on cases that “the HTA organization is clearly separated
Table 5 Summary of currently relevant ethical issues in ASCT in breast cancer patients
Ethical issue
Health technology
Harm: Introduction of ASCT into clinical practice took place without further evaluation in clinical trials.
Harm: Incidence of severe side effects, risk of mortality and some negative impact on quality of life in the survivors
Trust: The only two trials which showed benefit in overall survival were found to be fraudulent (Bezwoda fraud). This caused significant effects on
further research and the doctor-patient relationship as well as a lack of trust in oncology and the trial investigators. In consequence ASCT in breast
cancer remains a stigmatized technology and of great symbolic value.
Uncertainty: It is unknown to date whether there is any evidence of a benefit of ASCT for some subgroups of breast cancer patients and, if so,
whether this group would benefit more from an existing alternative.
External validity: The trials are only representative for highly specialised centres.
Alternatives: Safer procedures than ASCT do exist
Patients
Last chance therapy in metastatic breast cancer: As a consequence of this status patients postpone preparing for death. Attention is drawing away
from more appropriate efforts to minimize symptoms and enhance the quality of life for terminally ill patients and their families. Recent publications
discuss the right of patients to aggressive, toxic and expensive treatment - even untested with insufficient evidence on effectiveness and safety if it
is potentially life-saving or life-prolonging.
Patient autonomy: Patients were faced with the decision to consent to a hopefully life prolonging but also potentially fatal treatment. There are
some suggestions that patients are insufficiently informed and patient understanding is not always ensured.
Technological imperative: ASCT with the potential to benefit women with a life-threatening disease raises new hope for patients and physicians.
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from decision-makers it may be enough to describe the
different values, attitudes and arguments that should be
considered by the decision-makers”. In this context, we
prepared this review as a descriptive assessment. This
may assist decision-makers in their decision process - in
addition to the related results of the effectiveness assess-
ment, and if applicable, on information related to the
economic evaluation and the identified social, legal and
organizational issues.
We did a descriptive assessment by adapting the
methods of effectiveness assessment. While the adapted
method on information retrieval is published [5] a more
detailed presentation of the whole working process is
scheduled to be a separate publication on methods of
preparing systematic reviews on ethical issues as part of
health technology assessments. Some of the arguments
discussed in the publications are of historical value or
are currently of less importance than they were in the
1990s, such as the premature implementation of the
non-evaluated new technology in clinical practice.
Some results of past trials are fraudulent, but they
continue to have an impact. For this reason, previously
relevant ethical issues regarding this technology cannot
be neglected.
The Socratic approach was chosen because of direct
applicability by Hofmann’s question list. In practice, and
when a time restricted work flow is required, this has
been an important advantage over to some other exist-
ing methodological approaches. Other approaches would
also be able to address the central ethical dimensions,
but some of the existing methodological approaches -
with only one conceptual framework - would require
additional content. Moreover, the Socratic approach has
the advantage of being more comprehensive and paying
attention to values related to the assessment itself.
All dimensions of Hofmann’s question list could be
addressed through the literature. No arguments were
identified in the literature, which could not be assigned
to one of the questions, and some issues identified
could be assigned to more than one question. The find-
ings of the ASCT example suggest that some questions
could be summarized. In general, there is a tendency to
lose first-order experiences of patients or patient groups
by analyzing the (scientific) published literature. This is
not the case in our example. Our retrieval results
included some first-hand reports. Given that the
assessed technology is not new, probably most reported
first-hand experiences were covered by the scientific
publications.
The synthesis was done in the context of European
populations. From the viewpoint of other members of
society, such as people with different social or cultural
context, some issues may be missing from our presenta-
tion, or the presented issues may differ from their
values. Our screening process excluded such variation in
values. Furthermore, the presented arguments differently
impact different healthcare systems and patient popula-
tions around the world.
Conclusions
Regarding ASCT in breast cancer, some important ethi-
cal issues remain, which should be integrated into a
comprehensive health technology assessment and be
considered by both decision-makers and clinicians. The
reflexive Socratic approach by means of the questions
list by B. Hofmann proved to have good feasibility for
synthesizing these issues. In our experience the 33 ques-
tions posed by Hofmann were very precise and exhaus-
tive. Nevertheless, there could be other health
technologies associated with ethical issues which are not
being addressed or not being addressed in adequate
detail by Hofmann’s questions list.
The specific information retrieval identified the rele-
vant literature with an appropriate sensitivity and preci-
sion. The selection process of identified publications on
ethical issues that were included in the assessment and
assigned to the questions and the ethical dimensions
turned out to be a feasible approach.
In conclusion, our systematic literature review appears
to be more qualified and comprehensive than statements
from experts without a systematic review of relevant
issues. This implies that conducting methodological high-
quality reviews on ethical issues requires appropriate qual-
ity criteria and methodological standards to be defined
and applied in ethics research and publication writing.
It may be useful to integrate the results of the sys-
tematic review on ethical issues into a HTA on the
topic and to present them in a more reader-friendly for-
mat. Since our project was a pilot project an integration
of the presented results in the HTA was not possible.
Further applications are recommended to validate this
approach in a different context. There will be topics in
which literature analyses are not justified or too few
publications exist, and there are topics with inherent
ethical conflicts, in which literature analyses are not
appropriate. However, there are many topics and con-
text situations in which descriptive reviews of ethical
issues are appropriate.
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